ANZCTR search results

The optimal duration of adjuvant chemotherapy in premenopausal patients with operable early stage breast cancer is currently unknown and it is thought that relapse of disease following adjuvant therapy may be due to the presence of cells which are non-responsive to first cycles of treatment. Therefore, IBCSG VI will investigate whether 3 cycles of initial adjuvant chemotherapy are as effective as 6 cycles and whether the addition of 3 cycles of chemotherapy after a treatment-free interval is as effective as administering an initial course of chemotherapy alone in premenopausal patients.

This study plans to investigate whether statements made during intravenous induction of anaesthesia with propofol affect the perception of pain on injection.

This study will use the best quality research methods to test whether providing a 6-month individualised exercise and nutrition program to hip fracture patients soon after injury improves walking and other important health outcomes. Patients will be followed for 12 months to determine what difference the exercise and and nutrition programs make. If they help then health services will have the evidence they need to recommend this type of program to the growing number of older Australians that suffer a hip fracture.

The primary purposes of this study are: 1). To test whether HPV 6 virus like particles given as a vaccine are therapeutic for (ie prevent recurrence after conventional destructive treatment, or prolong the interval to recurrence after conventional destructive treatment) recurrent respiratory papillomatosis. 2). To confirm that this experimental vaccine is safe when used in this way. The vaccine is designed to encourage the body’s defences against infection to attack cells infected by HPV. This study will test different doses of the vaccine to see if they work.

The aim of this study is to examine whether the use of acupuncture improves the characteristics of the endometrium associated with implantation and pregnancy. Women will be randomised to receive acupuncture or standard care (control group). Women will be randomised at day 9 subject to the result of ultrasound and blood test. The endometrium will be assessed by vaginal ultrasound and the endometrium thickness and pattern recorded. The ultrasound will be performed by a fertility specialists blind to the study group (routine scan) at day nine to assess timing for egg retrieval. Further ultrasound measurements will be undertaken at the time of Embryo Transfer (ET) and an extra ultrasound undertaken one week following egg retrieval. Routine bloods will be taken prior to egg retrieval and additional blood will be taken on day seven following egg retrieval. Routine measurement of plasma oestradiol and progesterone will be taken. Study group : Treatment with acupuncture Acupuncture points to be used will be selected according to the individual Traditional Chinese Medicine (TCM) diagnosis, and at the time of the first treatment. The second treatment will be administered 25 minutes prior to embryo transfer. Classical acupuncture points pericardium 6 (PC6), Spleen 8 (SP8), Liver 3 (LR3), Stomach 29 (ST29), and Conception vessel (CV4) will be used. Auricular acupuncture points Shenmen, Zhigong, Neifenmi and Naodian will also be used. The third treatment will be administered 25 minutes after embryo transfer using acupuncture points Stomach 36 (ST36), Spleen 6 (SP6), and Spleen 10 (SP10). Auricular points Shenmen, Zhigong, Neifenmi and Naodian will be also be needled. Seirin acupuncture needles will be inserted to tissue level and stimulated manually to elicit the Deqi response. Needles will be retained for 25 minutes in each treatment. Study group 2: Standard care The standard treatment protocols for In Vitro Fertilization (IVF) and embryo transfer will be followed.

To study the safety of Ha44 after topical administration. Safety will be assessed by physical examination, including detailed assessment of scalp, face, eyes and ears, vital signs, 12-lead electrocardiogram, laboratory tests including haematology, clinical chemistry and urinalysis and adverse events. Ha44 is a novel insect ovicide.

Tamoxifen is a hormone tablet that improves cure rates in women with early breast cancer. Letrozole is a new hormone tablet that has recently been shown to work in advanced breast cancer. This international trial will determine if in women with early breast cancer, Letrozole is as good or better than tamoxifen, and whether taking both together is better still.

The best treatment for some women with early breast cancer includes a few months of chemotherapy after their surgery. However, even with the best treatment, the cancer sometimes re-occurs. Trastuzumab, also known as Herceptin, is a new drug that targets breast cancer cellls that have a special receptor (HER2) on them. Trastuzumab is benefical for women with advanced breast cancers that have HER2. This large, international trial will determine if adding Trastuzumab to best standard treatment improves cure rates for women with early breast cancers with HER2. It will also determine whether it is better to continue treatment with Trastuzumab for 1 or 2 years.

MOSAIC is a community randomised trial which examines whether mentor mothers can reduce partner abuse and depression, and strengthen health, wellbeing and mother-child bonds in women who are pregnant or have children under 5, attending upskilled and supported Maternal and Child Health (MCH) nurses or GPs. Mentor mothers (MMs) are para-professional trusted community women with additional training in domestic violence and parenting skills, who provide home-visiting, empowerment, advocacy and support to women pregnant or with children under 5, identified as abused or symptomatic of abuse by their GP or nurse. AIMS: The study’s primary aims are: • to reduce partner abuse or depression by 16% among women pregnant or with children under 5 whom GPs or MCH nurses identify as abused or at risk Its secondary aims are: • to strengthen infrastructure support for GP and nurse management of partner abuse, by enhancing effective inter-sectoral collaboration between general practice, MCH nurse teams and community-based family violence networks • to enhance health professional case management of family members living with partner abuse